Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04792502 |
| Title | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Adam Olszewski |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Yale Cancer Center | NOT_YET_RECRUITING | New Haven | Connecticut | 06511 | United States | Details |
| Rutgers Cancer Institute of New Jersey | RECRUITING | New Brunswick | New Jersey | 08901 | United States | Details |
| Lifespan Cancer Insitute | RECRUITING | Providence | Rhode Island | 02903 | United States | Details |